Continuous-Infusion Carboplatin in Combination with Idarubicin or Mitoxantrone for High-Risk Acute Myeloid Leukemia: A Randomised Phase II Study-Reference-Cited by-同舟云学术

Continuous-Infusion Carboplatin in Combination with Idarubicin or Mitoxantrone for High-Risk Acute Myeloid Leukemia: A Randomised Phase II Study

Published:1999-01 Issue:1-2 Volume:36 Page:45-55
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Belhabri Amine,Thomas Xavier,Troncy Jacques,Assouline David,Michallet Mauricette,Wattel Eric,Tigaud Jean Dominique,Blanc Michel,Fiére Denis,Archimbaud Eric

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428199909145948

Reference59 articles.

1. Acute myelogenous leukemia: recent advances in therapy

2. Phase I study of carboplatin given on a five-day intravenous schedule.

3. Phase 1 study of carboplatin in patients with advanced cancer, intermittent intravenous bolus, and 24-hour infusion.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review;Annals of Hematology;2018-04-21

2. The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemia;Cochrane Database of Systematic Reviews;2015-06-03

3. Structural investigation of idarubicin–DNA interaction: Spectroscopic and molecular docking study;International Journal of Biological Macromolecules;2013-09

4. The therapy of relapsed acute leukaemia in adults;Blood Reviews;2004-03

5. Current Awareness;Hematological Oncology;2000